A Convergence-Based Framework for Cancer Drug Resistance

被引:179
作者
Konieczkowski, David J. [1 ]
Johannessen, Cory M. [2 ]
Garraway, Levi A. [3 ]
机构
[1] Harvard Radiat Oncol Program, Boston, MA 02114 USA
[2] Broad Inst, Cambridge, MA 02142 USA
[3] Eli Lilly & Co, Indianapolis, IN 46225 USA
关键词
CELL LUNG-CANCER; METASTATIC BREAST-CANCER; NEUROENDOCRINE PROSTATE-CANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; BRAF INHIBITOR RESISTANCE; ANDROGEN-RECEPTOR GENE; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; TARGETED THERAPY; RAF INHIBITION;
D O I
10.1016/j.ccell.2018.03.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite advances in cancer biology and therapeutics, drug resistance remains problematic. Resistance is often multifactorial, heterogeneous, and prone to undersampling. Nonetheless, many individual mechanisms of targeted therapy resistance may coalesce into a smaller number of convergences, including pathway reactivation (downstream re-engagement of original effectors), pathway bypass (recruitment of a parallel pathway converging on the same downstream output), and pathway indifference (development of a cellular state independent of the initial therapeutic target). Similar convergences may also underpin immunotherapy resistance. Such parsimonious, convergence-based frameworks may help explain resistance across tumor types and therapeutic categories and may also suggest strategies to overcome it.
引用
收藏
页码:801 / 815
页数:15
相关论文
共 173 条
[1]   Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].
Akbay, Esra A. ;
Koyama, Shohei ;
Carretero, Julian ;
Altabef, Abigail ;
Tchaicha, Jeremy H. ;
Christensen, Camilla L. ;
Mikse, Oliver R. ;
Cherniack, Andrew D. ;
Beauchamp, Ellen M. ;
Pugh, Trevor J. ;
Wilkerson, Matthew D. ;
Fecci, Peter E. ;
Butaney, Mohit ;
Reibel, Jacob B. ;
Soucheray, Margaret ;
Cohoon, Travis J. ;
Janne, Pasi A. ;
Meyerson, Matthew ;
Hayes, D. Neil ;
Shapiro, Geoffrey I. ;
Shimamura, Takeshi ;
Sholl, Lynette M. ;
Rodig, Scott J. ;
Freeman, Gordon J. ;
Hammerman, Peter S. ;
Dranoff, Glenn ;
Wong, Kwok-Kin .
CANCER DISCOVERY, 2013, 3 (12) :1355-1363
[2]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[3]   WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors [J].
Anastas, Jamie N. ;
Kulikauskas, Rima M. ;
Tamir, Tigist ;
Rizos, Helen ;
Long, Georgina V. ;
von Euw, Erika M. ;
Yang, Pei-Tzu ;
Chen, Hsiao-Wang ;
Haydu, Lauren ;
Toroni, Rachel A. ;
Lucero, Olivia M. ;
Chien, Andy J. ;
Moon, Randall T. .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (07) :2877-2890
[4]  
[Anonymous], CELL
[5]   AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Lu, Changxue ;
Wang, Hao ;
Luber, Brandon ;
Nakazawa, Mary ;
Roeser, Jeffrey C. ;
Chen, Yan ;
Mohammad, Tabrez A. ;
Chen, Yidong ;
Fedor, Helen L. ;
Lotan, Tamara L. ;
Zheng, Qizhi ;
De Marzo, Angelo M. ;
Isaacs, John T. ;
Isaacs, William B. ;
Nadal, Rosa ;
Paller, Channing J. ;
Denmeade, Samuel R. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Luo, Jun .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038
[6]   Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade [J].
Arora, Vivek K. ;
Schenkein, Emily ;
Murali, Rajmohan ;
Subudhi, Sumit K. ;
Wongvipat, John ;
Balbas, Minna D. ;
Shah, Neel ;
Cai, Ling ;
Efstathiou, Eleni ;
Logothetis, Chris ;
Zheng, Deyou ;
Sawyers, Charles L. .
CELL, 2013, 155 (06) :1309-1322
[7]   Overcoming mutation-based resistance to antiandrogens with rational drug design [J].
Balbas, Minna D. ;
Evans, Michael J. ;
Hosfield, David J. ;
Wongvipat, John ;
Arora, Vivek K. ;
Watson, Philip A. ;
Chen, Yu ;
Greene, Geoffrey L. ;
Shen, Yang ;
Sawyers, Charles L. .
ELIFE, 2013, 2
[8]   Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer [J].
Bardelli, Alberto ;
Corso, Simona ;
Bertotti, Andrea ;
Hobor, Sebastijan ;
Valtorta, Emanuele ;
Siravegna, Giulia ;
Sartore-Bianchi, Andrea ;
Scala, Elisa ;
Cassingena, Andrea ;
Zecchin, Davide ;
Apicella, Maria ;
Migliardi, Giorgia ;
Galimi, Francesco ;
Lauricella, Calogero ;
Zanon, Carlo ;
Perera, Timothy ;
Veronese, Silvio ;
Corti, Giorgio ;
Amatu, Alessio ;
Gambacorta, Marcello ;
Diaz, Luis A., Jr. ;
Sausen, Mark ;
Velculescu, Victor E. ;
Comoglio, Paolo ;
Trusolino, Livio ;
Di Nicolantonio, Federica ;
Giordano, Silvia ;
Siena, Salvatore .
CANCER DISCOVERY, 2013, 3 (06) :658-673
[9]   Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer [J].
Beltran, Himisha ;
Tagawa, Scott T. ;
Park, Kyung ;
MacDonald, Theresa ;
Milowsky, Matthew I. ;
Mosquera, Juan Miguel ;
Rubin, Mark A. ;
Nanus, David M. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) :E386-E389
[10]   Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets [J].
Beltran, Himisha ;
Rickman, David S. ;
Park, Kyung ;
Chae, Sung Suk ;
Sboner, Andrea ;
MacDonald, Theresa Y. ;
Wang, Yuwei ;
Sheikh, Karen L. ;
Terry, Stephane ;
Tagawa, Scott T. ;
Dhir, Rajiv ;
Nelson, Joel B. ;
de la Taille, Alexandre ;
Allory, Yves ;
Gerstein, Mark B. ;
Perner, Sven ;
Pienta, Kenneth J. ;
Chinnaiyan, Arul M. ;
Wang, Yuzhuo ;
Collins, Colin C. ;
Gleave, Martin E. ;
Demichelis, Francesca ;
Nanus, David M. ;
Rubin, Mark A. .
CANCER DISCOVERY, 2011, 1 (06) :487-495